Previous 10 | Next 10 |
Momenta Pharmaceuticals, Inc. (MNTA) Q3 2019 Earnings Conference Call October 31, 2019, 08:30 AM ET Company Participants Patty Eisenhaur - VP of IR and Corporate Communications Craig Wheeler - President & CEP Michelle Robertson - CFO Young Kwon - Chief Business Officer Sa...
Momenta Pharmaceuticals (NASDAQ: MNTA ): Q3 GAAP EPS of -$0.45 beats by $0.05 . Revenue of $6.39M (-57.1% Y/Y) beats by $1.15M . Press Release More news on: Momenta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial results for the third quarter...
Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...
CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for ...
CAMBRIDGE, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc . (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the appointment of Donna Grogan, M.D....
The following slide deck was published by Momenta Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Momenta Pharmaceuticals, Inc. (MNTA) Q2 2019 Results Earnings Conference Call August 02, 2019, 08:30 AM ET Company Participants Patty Eisenhaur - Vice President of Investor Relations and Corporate Communications Craig Wheeler - President and Chief Executive Officer Michelle Rober...
Momenta Pharmaceuticals ( MNTA ) Q3 results : Revenues: $5.2M (-60.0%); Product revenue: $3.3M (-72.0%); R&D revenue: $1.8M (+38.5%). More news on: Momenta Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Momenta Pharmaceuticals (NASDAQ: MNTA ): Q2 GAAP EPS of -$1.16 misses by $0.73 . More news on: Momenta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Momenta Pharmaceuticals Inc. Company Name:
MNTA Stock Symbol:
NASDAQ Market:
Momenta Pharmaceuticals Inc. Website:
Are These Top 3 Pharmaceutical Stocks On Your October Watchlist? Investing in pharmaceutical stocks is a popular trend in times of political or economic instability. This is because the demand for drugs will still be steady all year long, no matter what is happening in the world...
Chesapeake Utilities to Join S&P SmallCap 600 Chesapeake Utilities to Join S&P SmallCap 600 PR Newswire NEW YORK, Sept. 25, 2020 NEW YORK , Sept. 25, 2020 /PRNewswire/ -- Chesapeake Utilities Corp (NYSE:CPK) will replace Momenta Pharmaceuticals In...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...